Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.

Pediatric blood & cancer - 1 May 2017

Mayfield Jodi R, Czuchlewski David R, Gale James M, Matlawska-Wasowska Ksenia, Vasef Mohammad A, Nickl Christian, Pickett Gavin, Ness Scott A, Winter Stuart S

Abstract excerpt

A 17-year-old girl with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with persistent minimal residual disease (MRD) who underwent standard chemotherapy was found to have a BCR-ABL1-like gene expression pattern. Genome sequencing revealed a JAK2 mutation not previously described in BCP-ALL and a potential therapeutic target. Due to concern for an on-therapy relapse, the JAK2 inhibitor ruxolitinib was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm, Residual

Share to Nitriles

Share to Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Share to Pyrazoles

Share to Pyrimidines

Share to Stem Cell Transplantation

Source

Open in PubMed Open full text

Identifiers

PMID: 27860260
DOI: 10.1002/pbc.26328
PMCID: PMC5366086

Genes

JAK2
ABL1
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.PMID 27860260Read ↗

The JAK3Q988P mutation reveals oncogenic potential and resistance to ruxolitinib.Semantic proximity Read ↗

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway AlterationsSemantic proximity Read ↗

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.Semantic proximity Read ↗

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.Semantic proximity Read ↗

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.Semantic proximity Read ↗

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemiaSemantic proximity Read ↗

Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia.Semantic proximity Read ↗

The Role of the JAK-STAT Pathway in Childhood B-Cell Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Anlotinib Exerts Potent Antileukemic Activities in B-Cell Acute Lymphoblastic Leukemia Via Attenuation of PI3K/AKT/mTOR Signaling CascadeSemantic proximity Read ↗

Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.Semantic proximity Read ↗

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.Semantic proximity Read ↗

CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.